Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab in Heterozygous Familial Hypercholesterolemia
NCT01763918Phase 3Completed
- Sponsor
- Amgen
- Start
- Feb 2013
- Primary completion
- Nov 2013
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 3 trial of evolocumab in heterozygous familial hypercholesterolemia (HeFH), sponsored by Amgen. Started Feb 2013; status: completed.
02
Drugs
evolocumab
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NCT01763918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01763918.